Subtenon injection of natural leukocyte interferon α-2a in diabetic macular edema: A case report

BMC Ophthalmology

Volumn 13, Issue 1, 2013, Pages

  Cellini, Mauro ^a   Balducci, Nicole ^a   Strobbe, Ernesto ^a   Campos, Emilio C ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Central macular thickness; Diabetic macular edema; Interferon; Spectral domain optical coherence tomography; Subtenon injections

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; IMMUNOLOGIC FACTOR; RECOMBINANT PROTEIN;

AGED; ARTICLE; CASE REPORT; DIABETIC RETINOPATHY; DRUG EFFECT; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; RETINA MACULA EDEMA; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84886182264     PISSN: None     EISSN: 14712415     Source Type: Journal    
DOI: 10.1186/1471-2415-13-63     Document Type: Article

References (15)

1. Pathophysiology of diabetic macular edema. Singh A, Stewart JM, Int Ophthalmol Clin 2009 49 1 11
2. Photocoagulation for DME: early treatment diabetic retinopathy study report number 1. Early Treatment Diabetic Retinopathy Study Group, Arch Ophthalmol 1985 103 1796 1806 2866759
3. Corticosteroid use for diabetic macular edema: old fad or new trend? Stewart MW, Curr Diab Rep 2012 12 364 375 10.1007/s11892-012-0281-8 22581206
4. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Virgili G, Parravano M, Menchini F, Brunetti M, Cochrane Database Syst Rev 2012 12 12 CD007419
5. Pharmacology and therapeutic potential of interferons. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA, Pharmacol Ther 2012 135 44 53 10.1016/j.pharmthera.2012.03.006 22484806
6. Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Gillies MC, Su T, Microvasc Res 1995 49 277 288 10.1006/mvre.1995.1024 7643749
7. Subtenon injection of natural leucocytic interferon-α for treatment of diabetic macular edema. Cellini M, Strobbe E, Balducci N, Campos EC, Acta Ophthalmol 2011 89 248 213-214 10.1111/j.1755-3768.2009.01661.x
8. Effect of subtenon injection of natural leucocytic interferon-α for treatment of age-related choroidal neovascularisation. Cellini M, Strobbe E, Balducci N, Campos EC, Acta Ophthalmol 2011 89 248 211-212 10.1111/j.1755-3768. 2009.01661.x
9. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of Bevacizumab and Pegaptanib sodium in rabbits. Avci B, Avci R, Inan UU, Kaderly B, Invest Ophthalmol Vis Sci 2009 50 7 3438 3446 10.1167/iovs.08-2871 19255151
10. Apoptosis and interferons: role of interferon-stimulated genes as mediatore of apoptosis. Chawla-Sarkar M, Lindnere DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC, Apoptosis 2003 8 3 237 249 10.1023/A:1023668705040 12766484 (Pubitemid 36749609)
11. The role of interferon alfa in the therapy of conjunctival lymphoma in HIV + patients: a case report. Cellini M, Possati GL, Puddu P, Caramazza R, Eur J Ophthalmol 1996 6 475 477 8997596
12. Local chemiotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report. Blasi MA, Gherlinzoni F, Calvisi G, Sasso P, Tani M, Cellini M, Balestrazzi E, Ophthalmol 2001 108 559 562 10.1016/S0161-6420(00)00591-1 (Pubitemid 32179899)
13. Interferon-α therapy in noninfectious uveitis. Deuter C, Stübiger N, Zierhut M, Dev Ophthalmol 2012 51 90 97 22517207
14. Interferon alpha-2 for proliferative diabetic retinopathy after complete laser panretinal photocoagulation treatment. Leibovitch I, Loewenstein A, Alster Y, Rosenblatt I, Lazar M, Yassur Y, Rubinstein A, Ophthalmic Surg Lasers Imaging 2004 35 16 22 14750758 (Pubitemid 38057968)
15. Choroidal concentration of interferon after retrobulber injection. Lincoff H, Stango P, Movshovich A, Palleroni A, Madjarov B, Rivera R, Silverman R, Invest Ophthalmol Vis Sci 1996 37 2768 2771 8977493 (Pubitemid 27026563)